ClinicalTrials.gg
CompletedNCT07522944Updated Nov 6, 2026

AI-Guided Personalized Relaxation for Hemodialysis Patients

An interventional study of AI-Guided Relaxation Platform and Standard Hemodialysis Nursing Care in Renal Insufficiency, Chronic, Anxiety and Relaxation Therapy, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Alexandria University · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 6, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.

Enrollment
6th of 44
128 · median 64
Started
2026
with 8 others
No phase
23 of 64
5 open now
Registered
56th of 64
by date
Lead sponsor
7 of 64
Alexandria University

Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 6th largest by enrollment of the 44 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 with no phase, and was the 56th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in Egypt, or all of them as a file.
02

Study summary

Patients undergoing maintenance hemodialysis frequently experience impaired health-related quality of life, anxiety, and difficulties in coping with the long-term demands of treatment. Artificial intelligence (AI)-guided interventions may provide personalized psychological support and promote adaptive coping through tailored relaxation strategies.

This randomized controlled mixed-methods trial evaluates the effectiveness of an AI-guided personalized relaxation intervention delivered through a smartphone application among adults receiving maintenance hemodialysis. Participants are randomly assigned to either an intervention group receiving AI-guided personalized relaxation in addition to routine hemodialysis care or a control group receiving routine care alone. The 6-week intervention includes individualized breathing exercises, mindfulness practices, guided imagery, progressive muscle relaxation, and adaptive feedback generated according to participant characteristics, emotional responses, and engagement patterns.

The primary outcome is health-related quality of life measured using the Kidney Disease Quality of Life-36 (KDQOL-36™). Secondary outcomes include anxiety symptoms measured by the Generalized Anxiety Disorder-7 (GAD-7), coping strategies measured by the Brief COPE Inventory, and user acceptance of the AI-guided intervention. Qualitative interviews are conducted with intervention participants to explore their experiences, perceived benefits, feasibility, and acceptability of the intervention.

The study aims to determine whether AI-guided personalized relaxation can improve quality of life, reduce anxiety, and enhance coping among patients undergoing maintenance hemodialysis while providing insight into the acceptability and feasibility of integrating AI-supported psychosocial interventions into routine dialysis care.

The personalization system incorporate a pre-trained facial emotion recognition model using the smartphone's front-facing camera. Facial expressions will analyze in real time to classify emotional states (e.g., anxious, neutral, or relaxed) and adapt relaxation recommendations. Facial images will not stored, and the feature will used solely for intervention personalization after informed consent.

Sample size will estimated a priori using GPower (version 3.1) software for a two tailed analysis of difference between two independent means within -t- test family using the following parameters; effect size (Cohen's d = 0.64) which had been reported by Zhang et al. (2025), significance level of 0.05, a statistical power of 90%, and an allocation ratio of 1:1. The minimum sample size will require 106 participants (53 for each group). To compensate for an anticipated attrition rate of 20%, the sample size will increased to 128 participants (64 participants per group).

03

Conditions studied

  • Renal Insufficiency, Chronic
  • Anxiety
  • Relaxation Therapy
  • Maintenance Hemodialysis
  • Stress, Psychological
  • Quality of Life

Keywords

  • Hemodialysis, Hospital
  • Renal Dialysis
  • End-Stage Renal Disease (ESRD)
  • Psychological Distress
  • Anxiety
  • Artificial Intelligence
  • Digital Health
  • Relaxation Therapy
  • Mindfulness-Based Interventions
  • Coping Skills
  • AI-Guided Intervention
  • Quality of Life
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Adults aged 18 years or older. Diagnosed with end-stage renal disease (ESRD). Receiving maintenance hemodialysis for at least 3 months. Able to communicate and complete study questionnaires. Possession of, or access to, a smartphone capable of running the study application.

Willing and able to provide written . Exclusion Criteria Severe cognitive impairment or inability to complete study assessments. Severe psychiatric illness requiring acute treatment or hospitalization. Significant visual, hearing, or communication impairment preventing participation in the intervention.

Participation in another psychosocial, behavioral, or relaxation intervention study during the study period.

Inability or unwillingness to use the smartphone-based intervention.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Experimental: AI-Guided Relaxation Group

    Description: Participants received a 6-week AI-guided personalized relaxation program delivered through a smartphone application in addition to routine hemodialysis care. The intervention provided individualized relaxation exercises, including guided deep breathing, mindfulness-based relaxation, guided imagery, progressive muscle relaxation, calming audio sessions, and positive coping reinforcement messages. The AI system adapted recommendations based on participant characteristics, emotional responses, engagement patterns, and feedback. Participants completed three 20-30 minute sessions per week during and/or outside hemodialysis sessions.

    Device: AI-Guided Relaxation Platform

  • Active comparator
    Control Group

    Participants in this arm will receive only the standard nursing care and routine protocols typically provided during hemodialysis sessions at the study site. No AI-guided relaxation or digital intervention will be administered. Data will be collected at the same time intervals as the intervention group to serve as a baseline for comparison.

    Other: Standard Hemodialysis Nursing Care

Interventions

  • DeviceAI-Guided Relaxation Platform

    Participants received a 6-week AI-guided personalized relaxation program delivered through a smartphone application. The intervention included individualized breathing exercises, mindfulness-based relaxation, guided imagery, progressive muscle relaxation, calming audio sessions, and positive coping reinforcement messages. An AI-based personalization system adapted relaxation recommendations according to participant characteristics, emotional responses, engagement patterns, and user feedback. Participants completed three 20-30 minute sessions per week in addition to routine hemodialysis care.

  • OtherStandard Hemodialysis Nursing Care

    Participants in the control group will receive the routine standard of care provided during maintenance hemodialysis sessions at the study site. This includes standard medical and nursing protocols, monitoring of vital signs, and routine patient education. No AI-guided relaxation interventions will be administered to this group. Data collection (quality of life, anxiety, and coping assessments) was conducted at the same time intervals as the intervention group.

06

What researchers measure

Primary outcomes

  1. Health-Related Quality of Life (HRQOL)

    Health-related quality of life was assessed using the Kidney Disease Quality of Life-36™ (KDQOL-36™), a validated disease-specific instrument for patients undergoing hemodialysis. The questionnaire generates scores for the Physical Component Summary (PCS), Mental Component Summary (MCS), Burden of Kidney Disease, Symptoms/Problems of Kidney Disease, and Effects of Kidney Disease domains. Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.

Secondary outcomes

  1. Anxiety Symptoms (GAD-7)

    Anxiety symptoms were assessed using the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

    Time frame: baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.

  2. Change in Coping Strategies as Measured by the Brief Coping Orientation to Problems Experienced Inventory

    Assessed using the Brief Coping Orientation to Problems Experienced (Brief COPE) Inventory (Carver, 1997). The inventory consists of 28 items covering 14 subscales including active coping, planning, positive reframing, acceptance, emotional support, and behavioral disengagement, among others. Each item is scored on a 4-point Likert scale ranging from 1 ("I haven't been doing this at all") to 4 ("I've been doing this a lot"). Scores for each subscale range from a minimum of 2 to a maximum of 8. Higher scores on adaptive coping subscales indicate greater reliance on constructive coping strategies. Brief COPE subscale scores were assessed at baseline (T0), post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3), and analyzed longitudinally across all measurement points.

    Time frame: baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.

  3. Technology Acceptance of the AI-Guided Relaxation Program

    Technology acceptance was assessed using an adapted Technology Acceptance Model questionnaire measuring perceived usefulness, perceived ease of use, user satisfaction, and behavioral intention toward continued use of the AI-guided relaxation program. Higher scores indicate greater acceptance.

    Time frame: post-intervention (T1; 6 weeks).

  4. Qualitative Exploration of Participant Experiences

    Semi-structured interviews will be conducted with participants in the intervention group upon completion of the intervention period to explore their personal experiences, levels of engagement, perceived ease of use of the AI system, and overall satisfaction with the AI-guided relaxation sessions. The interviews will gather detailed insights into how the technology influenced participants' ability to cope with the dialysis procedure and manage treatment-related anxiety. Each interview will last approximately 20-30 minutes and will be audio-recorded with participants' prior informed consent. Data will be analyzed using thematic analysis following the six-phase framework described by Braun and Clarke (2006).

    Time frame: post-intervention (T1; 6 weeks).

07

Study locations

1 site
  • Faculty of Nursing, Alexandria University
    Alexandria, Alexandria Governorate 2500, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Sep 2026, 4 months.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 4 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Apr 2026, on Oct 23, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, last on Nov 6, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 13, 2026
StartActual
Apr 15, 2026was Mar 2026
Primary completionActual
Sep 10, 2026was Jul 2026
CompletionActual
Sep 13, 2026was Aug 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Faculty of Nursing, Alexandria University · Alexandria, Egypt
Oct 23, 2026
Start date
Mar 29, 2026→Apr 15, 2026
Oct 23, 2026
Primary completion
Jul 15, 2026→Sep 10, 2026
moved 2 times, Oct 23, 2026 – Nov 6, 2026
Study completion
Aug 30, 2026→Sep 13, 2026
Nov 6, 2026
Enrollment
125→128
Oct 23, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedInability or unwillingness to use the smartphone-based intervention. Withdrawal of consent at any stage of the study.
Oct 23, 2026
Interventions
Arm changed Control Group (No Intervention)→Control Group
Oct 23, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameHealth-Related Quality of Life (HRQOL)Baseline (T0), immediately post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3). → baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.
Oct 13, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 13, 2026
  • Time frameAnxiety Symptoms (GAD-7)Baseline (T0), immediately post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3). → baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.
  • Time frameChange in Coping Strategies as Measured by the Brief Coping Orientation to Problems Experienced InventoryBaseline (T0), immediately post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3). → baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.
  • Time frameTechnology Acceptance of the AI-Guided Relaxation Programpost-intervention (T1; 12 weeks). → Time Frame: post-intervention (T1; 6 weeks).
  • Time frameQualitative Exploration of Participant ExperiencesTime Frame: post-intervention (T1; 12 weeks). → Time Frame: post-intervention (T1; 6 weeks).
What changed on Oct 23, 2026
  • Time frameTechnology Acceptance of the AI-Guided Relaxation ProgramTime Frame: post-intervention (T1; 6 weeks). → post-intervention (T1; 6 weeks).
  • Time frameQualitative Exploration of Participant ExperiencesTime Frame: post-intervention (T1; 6 weeks). → post-intervention (T1; 6 weeks).
  • DescriptionChange in Coping Strategies as Measured by the Brief Coping Orientation to Problems Experienced Inventory: how it is measured was reworded
across 2 updates, Oct 13, 2026 – Oct 23, 2026
Show all 4 updates
  1. Nov 6, 2026
    Primary completion Aug 27, 2026→Sep 10, 2026
    Study completion Aug 30, 2026→Sep 13, 2026
  2. Oct 23, 2026
    1 site removed
    Show 1 removed
    • Faculty of Nursing, Alexandria University · Alexandria, Egypt
    Start date Mar 29, 2026→Apr 15, 2026
    Primary completion Jul 15, 2026→Aug 27, 2026
    Enrollment 125→128
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedInability or unwillingness to use the smartphone-based intervention. Withdrawal of consent at any stage of the study.
    Secondary outcomes 2 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameTechnology Acceptance of the AI-Guided Relaxation ProgramTime Frame: post-intervention (T1; 6 weeks). → post-intervention (T1; 6 weeks).
    • Time frameQualitative Exploration of Participant ExperiencesTime Frame: post-intervention (T1; 6 weeks). → post-intervention (T1; 6 weeks).
    • DescriptionChange in Coping Strategies as Measured by the Brief Coping Orientation to Problems Experienced Inventory: how it is measured was reworded
    Interventions Arm changed Control Group (No Intervention)→Control Group
    + 4 other changes: verification date, description, conditions and design details
  3. Oct 13, 2026
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameHealth-Related Quality of Life (HRQOL)Baseline (T0), immediately post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3). → baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.
    Secondary outcomes 4 time frame changed
    What changed in the outcomes
    • Time frameAnxiety Symptoms (GAD-7)Baseline (T0), immediately post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3). → baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.
    • Time frameChange in Coping Strategies as Measured by the Brief Coping Orientation to Problems Experienced InventoryBaseline (T0), immediately post-intervention (T1), 1-month follow-up (T2), and 3-month follow-up (T3). → baseline before the intervention (T0), immediately after completion of the 6-week intervention (T1), and at 1 month (T2) and 3 months (T3) after the end of the intervention.
    • Time frameTechnology Acceptance of the AI-Guided Relaxation Programpost-intervention (T1; 12 weeks). → Time Frame: post-intervention (T1; 6 weeks).
    • Time frameQualitative Exploration of Participant ExperiencesTime Frame: post-intervention (T1; 12 weeks). → Time Frame: post-intervention (T1; 6 weeks).
    + 1 other change: description
  4. Oct 9, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07522944
Responsible party
Mohamed Fakhry Ahmed Salem (Dr, Alexandria University) — Principal investigator
First posted
Apr 13, 2026
Start date
Apr 15, 2026
Primary completion
Sep 10, 2026
Completion
Sep 13, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion